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ABSTRACT: We report the eﬀects of the interaction of two camelid
antibody fragments, generally called nanobodies, namely cAb-HuL5 and a
stabilized and more aggregation-resistant variant cAb-HuL5G obtained by
protein engineering, on the properties of two amyloidogenic variants of
human lysozyme, I56T and D67H, whose deposition in vital organs including
the liver, kidney, and spleen is associated with a familial non-neuropathic
systemic amyloidosis. Both NMR spectroscopy and X-ray crystallographic
studies reveal that cAb-HuL5 binds to the α-domain, one of the two lobes of
the native lysozyme structure. The binding of cAb-HuL5/cAb-HuL5G strongly
inhibits ﬁbril formation by the amyloidogenic variants; it does not, however,
suppress the locally transient cooperative unfolding transitions, characteristic
of these variants, in which the β-domain and the C-helix unfold and which
represents key early intermediate species in the formation of amyloid ﬁbrils. Therefore, unlike two other nanobodies previously
described, cAb-HuL5/cAb-HuL5G does not inhibit ﬁbril formation via the restoration of the global cooperativity of the native
structure of the lysozyme variants to that characteristic of the wild-type protein. Instead, it inhibits a subsequent step in the
assembly of the ﬁbrils, involving the unfolding and structural reorganization of the α-domain. These results show that nanobodies
can protect against the formation of pathogenic aggregates at diﬀerent stages in the structural transition of a protein from the
soluble native state into amyloid ﬁbrils, illustrating their value as structural probes to study the molecular mechanisms of amyloid
ﬁbril formation. Combined with their amenability to protein engineering techniques to improve their stability and solubility, these
ﬁndings support the suggestion that nanobodies can potentially be developed as therapeutics to combat protein misfolding diseases.
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■ INTRODUCTION
Human lysozyme is a 130-residue protein belonging to the c-type
class of lysozymes and is present at high concentrations in various
tissues and ﬂuids including liver, articular cartilage, saliva, and
tears. Since its discovery in 1922 by Alexander Fleming, this
family of proteins has represented one of the most popular and
important model systems for understanding the complexity of
protein structure and function.1−3 In the early 1990s, mutational
variants of human lysozyme were found to be associated with a
familial systemic non-neuropathic amyloidosis in which large
quantities of the variant protein accumulate in a range of tissues
and organs, including the liver, spleen, and kidney.4 To date, nine
naturally occurring variants of human lysozyme have been
identiﬁed (Y54N, I56T, F57I, W64R, D67H, F57I/T70N,
T70N, W112R, and T70N/W112R),4−9 seven of which are
associated with disease (Y54N, I56T, F57I, W64R, D67H, F57I/
T70N and T70N/W112R) (Figure 1). The extensive knowledge
that has been accumulated on wild-type lysozyme (WT-HuL)
(for reviews, see refs 1, 2 and 10) has enabled detailed studies of
the eﬀects of both amyloidogenic (I56T and D67H),11−20 non-
amyloidogenic (T70N)21,22 and non-naturally occurring
(I59T)23 mutations on the properties of the protein including
its folding, stability and in vitro aggregation behavior. These
studies have shed light on the molecular basis of amyloid
formation by a globular protein, and revealed the link between
normal folding behavior that leads to biological function and
aberrant misfolding events that can lead to disease.24−26
These investigations have allowed the identiﬁcation of at least
two factors that regulate the amyloidogenicity of lysozyme.
The ﬁrst is a signiﬁcant decrease in the stability of the protein;
for example, at pH 5.0, the two amyloidogenic variants, I56T and
D67H, are ∼10 ± 2 °C less thermally stable than WT-
HuL,11,16,18,27,28 while the naturally occurring non-amyloido-
genic T70N variant is destabilized by only ∼4 °C.21,22 The
second factor is a reduction in the global cooperativity under
native conditions, which allows each amyloidogenic variant
to signiﬁcantly populate transient, partially unfolded species at
physiologically relevant temperature and pH, where the wild-type
protein is otherwise stable.4,12,27 Within these transient species,
the region of the protein structure involving the C-helix and the
β-domain (i.e., residues 42−100) is cooperatively unfolded,
whereas the remainder of the α-domain remains largely native-
like.12,27,28 This locally cooperative unfolding event is thought to
be critical for initiating the self-association of the lysozyme
variants into oligomeric species and subsequently into amyloid
ﬁbrils via intermolecular interactions between the locally
unfolded segments of several molecules.12,27,28 A study using
limited proteolysis has shown that the core region of human
lysozyme ﬁbrils formed in vitro by incubation at low pH and
moderate temperature involves residues 38−102 of the
protein,29 which corresponds to the β-sheet and the C-helix,
the region that undergoes the cooperative unfolding event.15,20
These results support the conclusion that unfolding of these seg-
ments of the chain triggers the formation of the amyloid structure.
We have shown previously that interactions with the N-
terminal fragment (VHH or nanobody) of two camelid heavy-
chain antibodies (HCAb),30 denoted cAb-HuL6 and cAb-
HuL22, which speciﬁcally recognize two diﬀerent epitopes on
the lysozyme structure, inhibit signiﬁcantly in vitro ﬁbril
formation by both the I56T and D67H variants.27,28,31 cAb-
HuL6 interacts with three residues of the loop between the
A- and B-helices within the α-domain (L15, G16, and Y20), four
residues of the long loop within the β-domain (A76, C77, H78,
and L79), and most residues of the C-helix (A90, D91, A94, C95,
K97, R98, and R101).28 Although no crystal structure of the
complex between cAb-HuL22 and WT-HuL is available,
competition binding experiments with a substrate analogue, as
well as WT-HuL enzymatic activity measurements in the pre-
sence of cAb-HuL22, show that it binds to residues located in the
active site of WT-HuL.31 Interestingly, despite the diﬀerent loca-
tion of their epitopes, the binding of each nanobody eﬃciently
suppresses the locally cooperative unfolding event of the
β-domain and C-helix for both the I56T and D67H variants
under physiologically relevant conditions, thus restoring the
global cooperativity of these variants to that characteristic ofWT-
HuL. The results of these studies strongly support the mecha-
nism of lysozyme aggregation in which the reduction of both
native stability and global cooperativity of the amyloidogenic
variants are crucial initial events on the pathway of aggregation.2
In the present work, we have isolated a novel nanobody,
referred to as cAb-HuL5, which binds to WT-HuL and the I56T
and D67H amyloidogenic variants. In contrast to the previously
reported nanobodies, cAb-HuL5 does not interact with any of the
residues ofHuL that are involved in the cooperative unfolding of the
β-domain and C-helix of amyloidogenic lysozyme variants. This
ﬁnding provides us with a unique opportunity to evaluate the
eﬀects of binding to non-amyloidogenic regions of HuL on the
formation of partially unfolded species, and consequently of
amyloid ﬁbrils, by amyloidogenic variants of HuL. We show that
the binding of the nanobody does not inhibit the formation of
partially unfolded intermediates of amyloidogenic HuL variants
under native conditions, highlighting the importance of the
location of the epitope for restoring the loss of global
Figure 1.Overlay of ribbon diagrams representing the structures ofWT-
HuL (gray) and the D67H variant (green); the structure of the I56T
variant is indistinguishable from that of WT-HuL. The α-helices are
labeled A−D, and the three 310 helices are also indicated. The four
disulﬁde bonds are shown in orange, and the Cα atoms of the
amyloidogenic mutations 54, 56, 57, 64, and 67 are represented as
magenta spheres. The T70N andW112Rmutations, colored in blue, are
not associated with disease unless they are in combination with a
substitution at another position (F57I/T70N and T70N/W112R). The
black arrows show the regions of the molecule (i.e., the two β-strands
(residues 42−55) and the long loop (residues 66−77) of the β-domain)
that are signiﬁcantly distorted in the D67H variant compared to those of
the WT-HuL and I56T proteins. The regions of the I56T and D67H
variants that unfold transiently in a cooperative manner are colored in
dark gray and dark green, respectively. The lysozyme structures were
generated from coordinates determined by X-ray diﬀraction studies
[PDB 1LYY (D67H), 1LOZ (I56T), and 1LZ1 (WT-HuL)] and
produced using MOLMOL.
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cooperativity due to destabilizing mutations in the amyloido-
genic variants of HuL. Nevertheless, the binding of cAb-HuL5G
(a very stable chimeric nanobody generated by grafting the three
complementarity determining regions (CDRs) of cAb-HuL5
onto the framework of cAb-HuL6) suppresses amyloid ﬁbril
formation very eﬀectively, revealing that the involvement of the
α-domain is a crucial step in the formation of amyloid ﬁbrils by
human lysozyme. These investigations demonstrate further the
versatility of nanobodies for isolating diﬀerent species present
along the aggregation pathway and conﬁrm that these
biomolecules can act as very valuable structural tools to uncover
the underlying molecular mechanisms of protein misfolding and
aggregation.32 We further show that nanobodies are particularly
attractive moieties compared to other antibody fragments due to
their simplicity and amenability to modiﬁcation by protein
engineering techniques, allowing them to be tailored towards
improved stability and potency to inhibit amyloid ﬁbril
formation; these characteristics are likely to be highly beneﬁcial
for therapeutic lead development.
■ MATERIALS AND METHODS
Generation and Selection of cAb-HuL5.A dromedary was
immunized with wild-type human lysozyme, as described
previously.33 A phage library containing the genes coding for
the variable domains of the heavy-chain antibodies (nanobodies)
was then generated usingmRNA extracted from the lymphocytes
of the immunized dromedary.34 A novel nanobody speciﬁc for
human lysozyme, denoted cAb-HuL5, was isolated by biopann-
ing from this phage library. cAb-HuL5 was expressed in
Escherichia coli and puriﬁed to homogeneity as described
previously.35
Generation of cAb-HuL5G. cAb-HuL5G is a chimeric
nanobody obtained by grafting the three complementarity
determining regions (CDRs) of cAb-HuL5 onto the framework
of cAb-HuL6, a nanobody found to be highly stable and resistant
to aggregation under the conditions used to induce in vitro ﬁbril
formation of the amyloidogenic variants of lysozyme.27,28,35
CDRs 1 and 2 of cAb-HuL5 were grafted onto the framework of
cAb-HuL6, using a PCR method36 and the following primers:
CDR1HuL5_HuL6_F (5′-CTGTTCAGCCTCCGGCCT-
TAGTACTACTGTCATGGCCTGGTTCCGCCAGG-3′)
and CDR2HuL5_HuL6_R (5′-GGAGTCGGCATAGTATGG-
GAAACCATCACCAGTATAAATAGCTGCGACCCCCTC-
GCG-3′). CDR 3 of cAb-HuL5 was grafted onto the CDR1/2
grafted-cAb-HuL6 using PfuI polymerase and the primers
CDR3HuL5_HuL6_R (5′-GACATCCACCACAAAGAACCG-
TACGAGAAAGCACCTGTCTTCGCTGCACAGTAGTA-3′)
and CDR3HuL5_HuL6_F (5′-CCGGGCGTATAATCACTG-
GGGCCAGGGGAC-3′). The linear PCR fragment was inserted
into the pHEN6 expression vector33 by ligation with T4 DNA
ligase, transformed into E. coli WK6 (Δ(lac-proAB)galEstrA
[F′ lacIq lacZΔM15 proAB+]) CaCl2 competent cells and its
sequence was conﬁrmed by DNA sequencing analysis. The cAb-
HuL5 loop-grafted variant, denoted cAb-HuL5G, was expressed
and puriﬁed in the same way as cAb-HuL5.
Expression and Puriﬁcation of Human Lysozyme.Wild-
type human lysozyme, including uniformly 15N-labeled protein,
was expressed in Pichia pastoris and puriﬁed as previously
described.22 The I56T and D67H lysozyme variants, including
uniformly 15N-labeled proteins, were expressed in Aspergillus
niger and puriﬁed following established protocols.35,37
The lysozyme concentration was determined by absorbance
measurements using a calculated molar extinction coeﬃcient of
36 940 cm−1 M−1.38
Surface Plasmon Resonance Measurements. The
aﬃnity of the nanobodies for the various lysozyme variants was
determined using surface plasmon resonance following protocols
described previously.35 The nanobody concentrations were deter-
mined using a calculated extinction coeﬃcient of 34 045 cm−1 M−1
for both cAb-HuL5 and cAb-HuL5G.38
Thermal Denaturation Monitored by Circular Dichro-
ism (CD) Spectroscopy. The thermal denaturation of cAb-
HuL5 and cAb-HuL5G was followed at 237 nm, since at this
wavelength there is a large diﬀerence between their far UV-CD
spectra recorded at 25 and 95 °C, respectively. Thermal
unfolding was monitored in 0.1 M sodium citrate at pH 5.5
containing 3M urea, the buﬀer used to initiate aggregation of the
amyloidogenic lysozyme variants. The temperature was
increased monotonically from 25 to 90 °C at a rate of 0.5 °C·
min−1. The data obtained from the buﬀer alone was subtracted
from the melting curves of the samples containing a nanobody.
The resulting data were then ﬁtted to a two-state unfolding
model, using eq 1:
=
+ + + Δ −
+ Δ −
y
y m T y m T H R T T
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N N D D m m
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where y is the CD signal at 237 nm, yN and yD are the CD signals
for the native and denatured states of the protein at 0 °C,
respectively, T is the temperature in °C, R is the gas constant in
J·mol−1·°C−1, Tm is the midpoint of the heat-induced unfolding
in °C, ΔHm is the Van’t Hoﬀ enthalpy at Tm, and mN and mD are
the slopes for the pre- and post-unfolding baselines, respectively.
Nonlinear regression analysis was performed using the program
Origin 7.0 (MicroCal, Northampton, MA, USA).
Kinetics of Aggregation of D67H Lysozyme in the
Presence of cAb-HuL5G. Protein samples containing the
D67H variant alone (6.8 μM), the D67H/cAb-HuL5G complex
(both proteins at 6.8 μM or in some cases with a 2-fold excess of
cAb-HuL5G, i.e., 13.6 μM), and the cAb-HuL5G fragment alone
(14 μM) were prepared in 0.1 M sodium citrate buﬀer pH 5.5
with 3 M urea and passed through 0.22 μm ﬁlters. Samples were
placed in quartz cuvettes of 1 cm path length and stirred
vigorously at 48 °C. Right angle light scattering at 430 nm was
recorded every 1min for each sample using a Cary 400 scan UV−
visible spectrophotometer (Varian, CA, USA) with a slit width of
5 nm. 50 μL aliquots from each sample were taken at various time
points throughout the reaction to be analyzed by transmission
electron microscopy (TEM). To determine the eﬀects of the
cAb-HuL5G:D67H ratio on the kinetics of aggregation of the
D67H variant, samples were prepared using 14 μM cAb-HuL5G
and either 3.4 or 1.24 μMD67H lysozyme (i.e., corresponding to
4:1 and 11.2:1 molar ratios of cAb-HuL5G:D67H) in 3 M urea,
0.1 M sodium citrate buﬀer at pH 5.5, and incubated at 48 °C
under stirring conditions in quartz cuvettes. The light scattering
at 430 nm was measured at right angles in a Cary Eclipse
ﬂuorimeter (Varian, Walnut Creek, CA, USA).
Transmission Electron Microscopy. Samples were applied
to formvar carbon-coated grids (Agar Scientiﬁc, Stansted, UK)
and then stained with 2% uranyl acetate, and examined using a
Philips CEM 100 transmission electron microscope operating at
80 kV.
Mass Spectrometry. The I56T and D67H variants were
deuterated at exchangeable sites by unfolding in 6 M deuterated
The Journal of Physical Chemistry B Article
dx.doi.org/10.1021/jp403425z | J. Phys. Chem. B 2013, 117, 13245−1325813247
guanidinium chloride solutions, followed by dilution with
10 volumes of deuterated buﬀer (50 mM deuterated acetic acid
pH* 5.0) to refold the proteins. The proteins were concentrated
and subsequently diluted with D2O for eight cycles to
remove guanidinium chloride, using Centri-pre-3 concentrators
(Amicon, Millipore, Watford, UK). For the experiments in the
presence of cAb-HuL5, the deuterated lysozyme variant and the
protonated cAb-HuL5 fragment were combined immediately
before the H/D exchange experiments were performed to give a
stoichiometric molar ratio of lysozyme:cAb-HuL5 = 1:2
(to ensure all the lysozyme variants were in the antibody-
bound state). H/D exchange was initiated by diluting 1 volume
of the protein solution into 15 volumes of 100 mM ammonia/
formic acid buﬀer in H2O at pH 8.0 and 37 °C, and exchange
was allowed to proceed for various time points between 5 and
300 s. The H/D exchange was quenched by the addition of
7 volumes of 1 M acetic acid in H2O to generate a ﬁnal pH of 3.5.
The samples were immediately placed on ice before being
analyzed by electrospray mass spectrometry; samples were
analyzed at the base pressure of a LC-ToF spectrometer (Waters,
Milford MA, UK) with a capillary voltage of 1600 V and a cone
voltage of 80 V. Under these conditions, the antibody/lysozyme
complexes dissociate in the mass spectrometer, enabling
the mass distributions of the lysozyme molecules alone to be
determined readily and directly.28 No adjustment was made to
the total number of exchanged proton atoms for the remaining
6% deuterium present in the sample, and the mass spectra shown
in Figure 4 represent the convolution of the +8, +9, and +10 charge
states with minimal smoothing, converted to a mass scale.12,28
NMR Studies of the WT-HuL/cAb-HuL5 and I56T/cAb-
HuL5 Complexes. Two-dimensional [15N−1H]-HSQC spectra
of wild-type human lysozyme (uniformly 15N-labeled) in the
presence and absence of the unlabeled cAb-HuL5 fragment were
recorded at 35 °Cusing a Bruker Biospin Avance 700MHzNMR
spectrometer equipped with a cryo-platform (Bruker, Coventry,
UK). Samples of the nanobody/lysozyme complex weremade up
with a 2-fold molar excess of the antibody fragment to eﬀectively
ensure that all the lysozymemolecules were in the bound state, in
20 mM phosphate buﬀer pH 6.5 in 95% H2O/5% D2O. The
HSQC spectra were collected with 2048 and 256 complex points
in t1 (
1H) and t2 (
15N), and with sweep widths of 8389 and 2483
Hz in the 1H and 15N dimensions, respectively. The 1H and 15N
resonances of wild-type human lysozyme in complex with the
antibody fragment were assigned by 15N-edited 3D NOESY-
HSQC measurements. These spectra were collected with 2048,
74, and 138 complex points in t1 (
1H), t2 (
15N), and t3 (
1H),
respectively, and the observed NOE data for the antibody/
lysozyme complex were interpreted by using the assignments of
the free protein. All the NMR spectra were processed with
NMRPipe39 and Sparky (http://www.cgl.ucsf.edu/home/
sparky/). Similar NMR measurements were also performed
with the I56T variant and the I56T/cAb-HuL5 complex in
20mMsodium acetate buﬀer pH5.0 in 95%H2O/5%D2Oat 37 °C.
Crystallization and Structure Solution of the cAb-HuL5/
WT-HuL Complex. Single crystals of the cAb-HuL5/WT-HuL
complex were obtained by hanging drop vapor diﬀusion at
3.9 mg/mL, in 4.8 MNaCl, 0.1MHEPES pH 7, and 3% glycerol.
X-ray diﬀraction data from frozen crystals were obtained using
the EMBL BW7B beamline equipped with a MARCCD 165mm
detector at the DESY synchrotron facility (Hamburg, Germany).
The diﬀraction data were processed by DENZO and
SCALEPACK40 to determine the space group and to scale and
merge the data. Molecular replacement was performed by the
program Phaser41 using the structures of cAb-HuL6 and WT-
HuL in PDB entry 1OP9 as search models for, respectively, cAb-
HuL5 and WT-HuL, to obtain the phase information associated
with the structure factors. Model building and reﬁnement were
achieved using the programs Phenix Suite42 and Refmac5 as
implemented in the CCP4 suite.43 The graphics program Coot44
was used to interpret the electron density maps and for rebuild-
ing of the structure. Data collection and reﬁnement statistics are
listed in Table 1.
The structural and chemical properties of the cAb-HuL5/WT-HuL
interface were analyzed using the PDBePISA server at the EMBL
(http://www.ebi.ac.uk/msd-srv/prot_int/cgi-bin/piserver).45
The Lee and Richards algorithm, using a probe radius of 1.4 Å,
was used to calculate the change in solvent accessible surface area
(ΔASA) of both cAb-HuL5 and WT-HuL upon complex
formation.46 The residues of WT-HuL and cAb-HuL5 that
have atoms within 4 Å of each other in the complex were
considered to be interface residues. These interatom distances
were calculated using the program Contact, implemented in the
CCP4 software.47 The HBPLUS program,48 was used to
calculate the number of hydrogen bonds formed in the interface.
Figures were prepared with the program Pymol (www.pymol.org).
Binding of cAb-HuL5 to Amyloid Fibrils Monitored by
Tryptophan Fluorescence Measurements. Fibrils of the
D67H variant were prepared by incubating the D67H variant
protein (6.8 μM) in 0.1 M sodium citrate buﬀer pH 5.5
containing 3M urea at 48 °Cwith stirring for approximately 12 h.
The ﬁbrils were collected by centrifugation at 353 200 g and 25 °C
for 1 h using an Optima TLX ultracentrifuge (Beckman Coulter,
HighWycomb, UK), and then puriﬁed by three cycles of washing
with 1 mL of 0.1 M sodium acetate buﬀer, pH 5.5, and further
centrifuged at 353 200 g and 25 °C for 1 h. The ﬁbrils were
resuspended at a concentration of 0.4 mg/mL in 0.1 M sodium
acetate buﬀer pH 5.5 containing 0.4 mg/mL of cAb-HuL5.
After incubation for 1 h at 25 °C, the sample was centrifuged
at 353 200 g and 25 °C for 1 h. The ﬂuorescence emission
Table 1. Data Collection and Reﬁnement Statistics
Dataset cAb-HuL5/WT-HuL
Data Collection
space group P 43 21 2
cell dimensions
a, b, c (Å) 96.32, 96.32, 156.75
α, β, γ (deg) 90.00, 90.00, 90.00
resolution (Å) 1.95
Rsym 11.5 (54.0)
a
I/σI 23.3 (4.3)a
completeness (%) 99.9 (99.9)
redundancy 8.6 (7.6)a
Reﬁnement
resolution range (Å) 19.90−1.95 (2.10−1.95)
no. reﬂections 54 358
Rwork/Rfree 18.9/21.9
B-factors (Å2)
protein 24.6
water 28.1
rms deviations
bond lengths (Å) 0.007
bond angles (deg) 1.014
aThe values in parentheses represent those of the highest resolution
shell.
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spectrum of the supernatant was recorded on a Cary Eclipse
spectroﬂuorimeter at 25 °C between 300 and 440 nm. The
excitation and emission slit widths were 5 and 10 nm, respec-
tively, and the excitation wavelength was 295 nm. For comparison
purposes, similar ﬂuorescence measurements were also per-
formed with a solution of 0.4 mg/mL cAb-HuL5 in 0.1M sodium
acetate, pH 5.5.
FTIR Measurements. Fibrils of the D67H variant were
prepared and puriﬁed as described above. The ﬁbrils were
resuspended, at ∼10 mg/mL, in 10 μL of 0.1 M sodium
acetate buﬀer pH 5.5. A total of 256 interferograms for each sample
were recorded on a Bruker Equinox 55 FTIR spectrometer
(Bruker, Coventry, UK) (purged with N2) bymeans of attenuated
total reﬂection (ATR) at 25 °C, and then subjected to Fourier
transformation. These signals were subtracted from those of the
buﬀer (0.1 M sodium acetate, pH 5.5) recorded under the same
conditions. The amide I region (1580−1720 cm−1) of each IR
spectrum was subjected to Fourier self-deconvolution and
subsequently ﬁtted to Gaussian functions to determine component
peaks using Grams/32 (Galactic Industries Co., NH, USA). Similar
IR measurements and data analysis were also performed with the
monomeric D67H variant (10 mg/mL) under similar conditions.
The percentage area of the amide I component was obtained by
integrating the area under each deconvoluted band; the area
corresponding to side chain contributions was not considered.
Isothermal Calorimetry Measurements. The interaction
of cAb-HuL5G with WT-HuL was measured by isothermal
calorimetry using a VP-ITC instrument (GE Healthcare,
Buckinghamshire, UK) with a cell volume of 1.4 mL. The
assay was performed in 100 mM sodium citrate buﬀer pH 5.5
containing 3M urea at 50 °C. Before analysis, lyophilized cAb-
HuL5G and WT-HuL were dissolved in water and extensively
dialyzed in 100 mM sodium citrate buﬀer pH 5.5 containing 3M
urea to ensure matching buﬀer compositions. Protein concen-
trations were measured spectrophotometrically, using molar
extinction coeﬃcients at 280 nm of 34 045 M−1 cm−1 for the
nanobody and 36 940 M−1 cm−1 for WT-HuL.38 After degassing
both protein solutions, cAb-HuL5G at 700 μM was loaded into
the syringe and WT-HuL at 10 μM was loaded in the ITC cell.
After an initial 4 μL injection of cAb-HuL5G, 27 injections of 10 μL
of nanobody were performed. The heat change for the last three
injections, for which binding reached saturation, was used to
estimate the heat of dilution and mixing, by subtraction of a straight
line through the last three points. The integrated heats for each
injection were then plotted against the molar ratio of nano-
body:WT-HuL, discarding the data for the ﬁrst two injections. Data
were processed using MicroCal Origin 7.0 software.
■ RESULTS
cAb-HuL5 Binds to the α-Domain of the Lysozyme
Structure. A new nanobody, cAb-HuL5, with high aﬃnity for
human lysozyme has been selected from a library of nanobody
genes cloned from the blood of a dromedary immunized with
WT-HuL according to a previously described procedure.34 This
antibody fragment was expressed in E. coli35 and puriﬁed to
homogeneity using previously described procedures.35 Its
binding properties to WT-HuL and the I56T and D67H
amyloidogenic variants were characterized by surface plasmon
resonance (SPR) measurements (Table 2).35
This antibody fragment displays an aﬃnity for the WT-HuL
(KD = 460 nM) that is lower than what is typically found for
other in vivo aﬃnity matured nanobodies (low nM range).35,49
The KD values measured for the cAb-HuL5/I56T and cAb-
HuL5/D67H variant complexes are, however, closely similar to
those for WT-HuL (410 and 460 nM for I56T and D67H
variants, respectively); this observation suggests that cAb-HuL5
recognizes a region of the protein structure that is essentially the
same in both variants and the wild-type structure (i.e., it does not
involve the β-strands (residues 42−55) or the long loop
(residues 66−77) within the β-domain; Figure 1).11
To deﬁne the epitope in detail, cAb-HuL5 was crystallized in
complex with WT-HuL and the structure of the complex was
solved at a resolution of 1.95 Å by using X-ray diﬀraction (Figure 2).
The formation of the cAb-HuL5/WT-HuL complex buries a
total of 661 Å2 of the accessible surface area (ASA) of WT-HuL
and 679 Å2 of the ASA of the antibody fragment, with 10 direct
hydrogen bonds being formed between the two proteins. These
interface properties are typical for nanobody−antigen and
antibody−antigen interfaces.50−52 There is, however, an
interesting diﬀerence in the polarities of the surface-binding
patches on the two proteins, as that of the nanobody is more
apolar (71%) than the corresponding patch of WT-HuL (61%).
The residues in the interface region of the complex (deﬁned as
residues of WT-HuL and cAb-HuL5 that have atoms which are
within 4 Å of each other in the complex) are R10, K13, R14, G16,
D18, G19, G22, I23, S24, A26, N27, V121, R122, and V130 for
WT-HuL and T30, Y50, T51, G52, D53, F55, P56, Y57, A100,
F101, S102, Y103, S105, and L106 for cAb-HuL5. The epitope of
cAb-HuL5 therefore consist of 14 residues of the lysozyme
molecule located primarily in the loop between the helices A and
B but also including some residues located at the beginning of
helix B and the C-terminal 310 helix and at the end of helix A.
Analysis of this interface reveals that cAb-HuL5, unlike the
previously characterized nanobodies raised against WT-HuL,
does not bind to any of the residues involved in the locally
cooperative unfolding of the amyloidogenic variants, that is
thought to be the trigger of amyloid ﬁbril formation.12,27,28
Moreover, comparing the structural alignment of lysozyme in
complex with cAb-HuL5 with structures of WT-HuL, previously
deposited in the protein databank, reveals that the binding of the
nanobody does not induce any conformational changes which
would cause the structure within the complex to deviate
signiﬁcantly from those found in other lysozyme crystal
structures (Figure S1 and Table S1, Supporting Information);
the average RMSD of the Cα atoms of lysozyme in the complex
compared to those of the structures listed (see Table S1,
Table 2. Kinetic and EquilibriumParameters for the Interaction of the cAb-HuL5 and cAb-HuL5GwithWT-HuL and the I56T and
D67H Amyloidogenic Variants Determined by SPR
WT-HuL D67H I56T
kon (M
−1 s−1)
10−5 koff (s
−1) KD (M) 10
7
kon (M
−1 s−1)
10−5 koff (s
−1) KD (M) 10
7
kon (M
−1 s−1)
10−5 koff (s
−1) KD (M) 10
7
cAb-HuL5 1.9 ± 0.2 0.088 ± 0.009 4.6 ± 0.1 2.0 ± 0.2 0.095 ± 0.001 4.6 ± 0.05 1.8 ± 0.02 0.073 ± 0.007 4.1 ± 0.43
cAb-HuL5G 4.10 ± 0.06 0.128 ± 0.001 3.1 ± 0.05 Nda Nda Nda Nda Nda Nda
aNot determined.
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Supporting Information) is 0.42 Å, while all the structures of the
free lysozyme molecules have averaged RMSD values between 0.1
and 0.2 Å; the slightly larger RMSD value found for the lysozyme
molecule within the cAb-HuL5:HuL complex is due to a small
diﬀerence in the conformation of the lysozyme protein backbone in
the region of residue 22 and residue 120, which are both part of the
binding site of cAb-HuL5 (Figure S1, Supporting Information).
Previous work has, however, shown that the dynamical
properties of regions far from the epitope can be aﬀected by
the binding of an antibody or antibody fragment via the long-
range propagation of very subtle structural perturbations.53 We
therefore studied the long-range eﬀects of the binding of cAb-
HuL5 by carrying out a series of NMR experiments. We ﬁrst
mapped the eﬀects on WT-HuL resulting from the binding of
cAb-HuL5 by comparing the HSQC spectrum of 15N-labeled
free WT-HuL with that of the labeled protein within the complex
with unlabeled cAb-HuL5.27,28 The chemical shift perturbations of
the amide resonances of WT-HuL were then analyzed to identify
those that are signiﬁcantly aﬀected by the interactions with
cAb-HuL5 (Figure 3a). Analysis of these data indicates that
35 residues of WT-HuL show signiﬁcant chemical shift
perturbations (|Δδ1H| ≥ 0.1 ppm or (|Δδ15N| ≥ 0.4 ppm)
upon binding to the antibody fragment (Figure 3b). Resonances
ofmost of the residues found tobe in direct contactwith cAb-HuL5 in
the X-ray structure are signiﬁcantly shifted relative to their position in
the unbound protein. Most of the additional residues with perturbed
chemical shift are located primarily in the A- and B-helices and,
additionally, in the 310 helix, which is adjacent to theC-helixwithin the
α-domain. These results strongly suggest that the nanobody binds to
WT-HuL in solution and in the crystal in the same way.
Similar NMR experiments were carried out with the I56T
variant (Figure S2, Supporting Information), which indicate that
cAb-HuL5 binds to this species in a closely similar manner to that
of WT-HuL. This observation is completely consistent with the
ﬁndings from SPR studies, which show that the aﬃnities of cAb-
HuL5 for the WT-HuL (KD = 4.6 × 10
−7 M), I56T (KD = 4.1 ×
10−7 M), and D67H (KD = 4.6× 10
−7 M) are essentially identical
(Table 1). In addition, none of the residues of the locally
unfolded region of the amyloidogenic intermediate (the C-helix
and the β-domain) show signiﬁcant chemical shift perturbations
upon binding to the nanobody except for Q58, I59 (located in
the β-domain at its interface with the α-domain), and V100
(located in the C-terminal end of the C-helix) (Figure 3c); again,
this observation is in marked contrast to the ﬁndings with the
other nanobodies that interact with human lysozyme.27,28,31
Indeed, the chemical shift of 11 and 26 residues from the region
that unfolds cooperatively were aﬀected upon binding of
respectively cAb-HuL6 and cAb-HuL22.
The Binding of cAb-HuL5 Does Not Restore the Global
Cooperativity of the I56T and D67H Variants. In order to
investigate the eﬀects of the binding of cAb-HuL5 on the
structural cooperativity of the I56T and D67H variants, pulse-
labeling H/D exchange experiments coupled with ESI-MS were
performed.11,12,27,28,31 Brieﬂy, the deuterated I56T and D67H
variants were ﬁrst subjected to exchange with protons of the
solvent H2O at pH 8.0 and 37 °C, and the exchange was
subsequently quenched at various time intervals by decreasing
the pH and the temperature of the sample. Similar experiments
were performed with both variants in the presence of a 2-fold
molar excess of cAb-HuL5. In the absence of cAb-HuL5, the
lysozyme variants show a clear bimodal distribution of mass
peaks over the time course of exchange (Figure 4a and c).
The peaks colored red arise from the lysozyme variants in their
native states undergoing H/D exchange through an EX2
mechanism as a result of local independent ﬂuctuations, while
those colored yellow result from the variant protein molecules
which have accessed the transient partially unfolded state at least
once and have therefore undergone exchange through an EX1
mechanism.11,12 In the presence of cAb-HuL5, this pattern of
behavior is qualitatively unchanged, indicating that the binding of
cAb-HuL5 does not suppress the locally cooperative unfolding
process, and hence does not restore the global cooperativity to
the lysozyme variants (Figure 4b and d). The relative intensities
of the mass peaks corresponding to the two species were
determined and the fractions of the lower mass species at the
diﬀerent time intervals calculated. The resulting time course of
the relative intensity of the peak corresponding to the lower mass
species provides a direct measure of the opening rate of the
locally cooperative unfolding event of the D67H and I56T
variants.12,27 Interestingly, the time constants for both variants in
complex with cAb-HuL5 (τD67H/cAb‑HuL5 = 7.9 ± 0.05 s;
τI56T/cAb‑HuL5 = 24.4 ± 8.6 s) are signiﬁcantly smaller than those
of the corresponding free variant proteins (τD67H = 25.2 ± 5.1 s;
τI56T = 36.8 ± 3.2 s), indicating that binding to the nanobody in
fact increases the rate of formation of the intermediate species for
both variants (Figure 4c and f).
The Binding of cAb-HuL5G Inhibits Fibril Formation by
the Amyloidogenic Lysozyme Variants. The eﬀect of the
cAb-HuL5 fragment on the propensity of the amyloidogenic
Figure 2. X-ray structure of the complex between WT-HuL and cAb-
HuL5. (a) Ribbon representation of the overall structure of the complex
between cAb-HuL5 (green) and WT-HuL (gray). The CDRs are
colored in magenta (CDR1), yellow (CDR2), and red (CDR3),
respectively. The disulﬁde bonds in WT-HuL are represented as red
sticks. (b) Stereo drawing of the details of the cAb-HuL5/WT-HuL
interaction. The side chains of the residues of both proteins that are
within 4 Å of each other are represented by sticks and are labeled; the
labels for the antibody fragment are color-coded according to the
antigen-binding loop to which they belong. (Figures were prepared
using Pymol, www.pymol.org.)
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variants to form ﬁbrils was investigated by light scattering
measurements of the D67H variant in 0.1 M sodium citrate
buﬀer pH 5.5 containing 3M urea and 48 °C, conditions shown
previously to give highly reproducible kinetics.28,31 Since the
properties of the I56T and D67H variants are identical,12,13,27,28
only one of them (i.e. the D67H) was chosen as a model protein
to test the ability of the nanobody to inhibit lysozyme formation.
When incubated under these conditions, uncomplexed D67H
aggregates within 60−100 min. In addition, however, despite being
muchmore stable than the lysozyme variant under these conditions,
cAb-HuL5 was itself found to aggregate signiﬁcantly into amyloid
ﬁbrils, on the same time scale as D67H alone (data not shown).
Thus, the eﬀects of binding cAb-HuL5 on the lysozyme aggregation
could not be investigated reliably under these conditions. We
therefore engineered a less aggregation prone version of cAb-HuL5,
referred to as cAb-HuL5G (see theMethods section), by grafting its
CDRs54 onto the extremely stable and non-aggregation-prone
scaﬀold of cAb-HuL6. The binding parameters of cAb-HuL5G to
WT-HuL are similar to thosemeasured for the cAb-HuL5 at pH 7.5
and 25 °C (Table 2). The midpoint of thermal unfolding (Tm) of
cAb-HuL5G in 0.1 M sodium citrate buﬀer pH 5.5 containing 3 M
urea is increased by ∼9.5 °C compared to that of cAb-HuL5 (i.e.,
75.5 ± 0.5 °C versus 66.0 ± 0.5 °C) (Figure 5).
The increased thermal stability of cAb-HuL5G results in a
greatly reduced tendency for the nanobody to aggregate under
these conditions, enabling the aggregation of D67H to be
monitored in the presence of a variety of molar equivalents of
cAb-HuL5G (Figure 6). These experiments show that binding of
the nanobody inhibits lysozyme aggregation, and in the presence
of one equivalent of cAb-HuL5G, the lag time prior to the
observation of light scattering of a 6.8 μM solution of D67H was
increased by ∼100 min, whereas with 2 equiv of cAb-HuL5G it
was increased by ∼125 min. Samples of the aggregation reaction
mixtures in the presence and absence of cAb-HuL5G at identical
time points (220 min) were taken for TEM analysis. The ﬁbrils
formed by D67H in the presence of 1 equiv of cAb-HuL5G
are similar in morphology to those formed by D67H alone
(Figure 6b−d). The samples with cAb-HuL5G, however, also
contained small globular species, morphologically similar to
species present at early time points (t = 98 min) in the samples of
D67H alone. Given that at t = 220 min the reaction of the D67H
variant in the presence of cAbHuL5G is close to its midpoint,
these species probably represent preﬁbrillar aggregates which
subsequently convert into mature ﬁbrils, as observed in similar
circumstances with many other systems.55−60
Figure 3. Overlaid [15N−1H]-HSQC NMR spectra of (a) WT-HuL (pH 6.5 and 35 °C) in the absence (blue) and presence (red) of cAb-HuL5. (b)
Chemical shift perturbations of WT-HuL induced by the binding of cAb-HuL5; red and blue bars represent the perturbations of the 1H and 15N
resonances, respectively. Residues experiencing a chemical shift change ≥ |0.4| ppm for 15N or ≥ |0.1| ppm for 1H resonances are considered to be
aﬀected signiﬁcantly by the binding of the nanobody. (c) Ribbon diagram ofWT-HuL showing the Cα atoms of the residues aﬀected signiﬁcantly by the
binding of cAb-HuL5 (blue spheres). The four disulﬁde bonds are shown in yellow. The β-domain and the adjacent C-helix that are unfolded in the
aggregation-prone intermediates (see text) are colored red. The peaks corresponding to G19 and Y20 (which are located in the loop between the A- and
B-helices) in the complex have not been assigned; their chemical shift diﬀerences are therefore not shown in the histograms. No unassigned peaks are
visible in the HSQC spectra of the complexes within 0.1 ppm (1H) and 0.4 ppm (15N) of the peak positions of G19 and Y20 in the HSQC spectrum of
the unbound lysozyme protein, suggesting that there are very signiﬁcant chemical shift perturbations for these residues upon binding to the antibody
fragment. Note that I59 and W109 (shown at blue sticks) whose side chains point toward the interface between the α- and β-domains are signiﬁcantly
aﬀected by the binding of cAb-HuL5. The structure ofWT-HuL was generated from its X-ray coordinates (PDB 1LZ1) and the diagram produced using
MOLMOL.
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As reported for the antibody fragment cAb-HuL22,31 the
aﬃnity constant of the nanobody:HuL interaction could be
signiﬁcantly perturbed as a result of the presence of the chemical
denaturant and the elevated temperature that are used in the
aggregation assay. The aﬃnity constant for the interaction of
the antibody fragment with WT-HuL in 0.1 M sodium citrate
buﬀer, pH 5.0, containing 3M urea and at 50 °C, was therefore
measured by ITC; the KD value obtained is 2.5 μM, which is
similar to the protein concentrations used in the aggregation
experiment (Figure S3, Supporting Information). A similar
analysis could not be performed for the cAb-HuL5G/D67H
interaction, as the D67H variant forms aggregates within the time
frame of the experiment in the ITC cell. When adding 1 (6.8 μM)
or 2 equiv (13.6 μM) of nanobody to the 6.8 μM D67H, we
calculate using the law of mass action that 3.1 and 1.5 μMD67H,
respectively, remains non-complexed in the aggregation experi-
ments described above. Therefore, in both cases, a signiﬁcant
amount of D67H is still free to form ﬁbrils, which eventually drives
the dissociation of the cAb-HuL5G/D67H complex toward
completion as D67H gets quasi-irreversibly sequestered into ﬁbrillar
aggregates. Subsequent experiments were therefore designed to test
the eﬀect of increasing the cAb-HuL5G/D67H stoichiometry on
the kinetics of aggregation of the D67H variant. We chose to reduce
the concentration of D67H, while keeping that of cAb-HuL5G
constant at 14 μM, as at 28 μM cAb-HuL5G shows signs of
aggregation under the experimental conditions used here.
The results show that the lag phase increases and the rate
of elongation of the ﬁbrils decreases at higher ratios of
Figure 4.H/Dexchange behavior of the I56T andD67Hvariants of human lysozyme in the absence andpresence of cAb-HuL5. Electrospraymass spectra of the
D67H (a, b) and I56T (d, e) variants following H/D exchange in the absence (a, d) and presence (b, e) of cAb-HuL5 at pH 8.0 and 37 °C. For the lysozyme/
nanobody mixtures, a 2-fold molar excess of cAb-HuL5 was added to ensure that eﬀectively all the lysozymemolecules were in the bound state. The mass peaks
colored red result from the gradual loss of deuterium atoms through an EX2mechanism due to local independent structural ﬂuctuations. Themass peaks colored
yellow arise from locally cooperative unfolding events that give rise toH/D exchange through an EX1mechanism.Note that the I56T andD67H variants exhibit
bimodal distributions ofmass peaks even in the presence of cAb-HuL5. Time courses of the relative intensities of the lowermass species (i.e., the yellow peaks) of
the (c)D67Hand (f) I56T variants in the absence and presence of cAb-HuL5.The data are the average of two experiments, and the bars show the error estimated
from these measurements. These data were ﬁtted to exponential functions to determine the time constants (τ) of the locally cooperative unfolding of the
lysozyme variants; τD67H = 25.2 ± 5.1 s; τD67H/cAb‑HuL5 = 7.9 ± 0.05 s; τI56T = 36.8 ± 3.2 s; τI56T/cAb‑HuL5 = 24.4 ± 8.6 s.
Figure 5. Thermal denaturation of cAb-HuL5 and cAb-HuL5G
monitored by far UV-CD spectroscopy. Ellipticity at 237 nm measured
as a function of temperature T (°C) for cAb-HuL5 (open circles) and
cAb-HuL5G (ﬁlled black circles) after subtraction of the buﬀer signal.
The red solid lines represent a nonlinear least-squares ﬁt to the data
using a two-state denaturation model described by eq 1.
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cAb-HuL5G/D67H; indeed, when an excess of between 4.0 and
11.2 equiv of cAbHuL5G was present, the aggregation of the
D67H variant was found to be completely inhibited, at least
within the time scalesmonitored in these experiments (up to 400min).
The α-Domain of the D67H Variant Substantially
Unfolds upon Forming Amyloid Fibrils. As the epitope of
cAb-HuL5 is essentially located in the loop between the A- and
B-helices of the α-domain in its native state (Figure 2), this
nanobody can serve as a structural probe to explore whether or
not some elements of the native structure are still present in the
α-domain of the D67H variant once it has converted into
amyloid ﬁbrils. In order to test this hypothesis, a sample
containing ﬁbrils of the D67H variant (∼0.4 mg/mL) was ﬁrst
incubated with cAb-HuL5 (0.4 mg/mL) at pH 5.5, ultra-
centrifuged to remove the ﬁbrils and any cAb-HuL5 with which it
is associated. The tryptophan ﬂuorescence emission spectrum of
the supernatant was then recorded, and for comparison, a control
sample containing only the antibody fragment (0.4 mg/mL) was
prepared and subjected to the same procedure. No diﬀerence in
the two spectra could be observed (Figure S4, Supporting
Information), indicating that the nanobody does not bind tightly
to the ﬁbrils. The results suggest, therefore, that the epitope
region does not maintain its native structure within the ﬁbrils.
This conclusion is strongly supported by FTIR spectra of
native lysozyme and of the lysozyme ﬁbrils in the amide I region
(Figure 7 and Table 3). The results highlight the fact that D67H
lysozyme undergoes profound conformational changes upon ﬁbril
formation (Figure 7 and Table 3); native D67H lysozyme con-
tains signiﬁcant quantities of both α and β structure, but in the
ﬁbrillar form, it exhibits ∼64% β-sheet structure. Note that the
decrease in α-helical structure is not attributable to the cleavage
of the α-domain from the D67H ﬁbrils, since SDS-PAGE analysis
Figure 6. Fibril formation by the D67H lysozyme variant in the absence
and presence of cAb-HuL5G. (a) Time course of the aggregation in
0.1 M sodium citrate buﬀer pH 5.5 containing 3M urea at 48 °C with
stirring of the D67H variant at 6.8 μM in the absence (red) and the
presence of 1 equiv (green) and 2 equiv (blue) of cAb-HuL5G. The
trace corresponding to the cAb-HuL5G alone and at a concentration
that is equivalent to a 2-fold molar excess of the complex is shown in
gray. Light scattering at 430 nm was recorded using a UV−visible
spectrophotometer with a slit width of 5 nm. Arrows on the plot indicate
the time points when samples were taken for TEM analysis. (b−d) TEM
images of the aggregation reaction of (b) the D67H variant at 98 min,
(c) the D67H variant at 220 min, and (d) the cAb-HuL5/D67H complex
at 220 min. The scale bar representing 100 nm is shown in each panel.
(e, f) Time course of the aggregation reactions of D67H at 3.4 μM (e)
and 1.24 μM (f), respectively, in the presence of 14 μM cAb-HuL5G,
resulting in the ratios 1:4 and 1:11.2 of D67H:cAb-HuL5G. The
aggregation trace for the D67H variant alone is shown in red, and the
trace corresponding to the D67H variant in the presence of cAb-
HuL5G is shown in green. The traces for the cAb-HuL5G alone are
shown in gray. Light scattering at 430 nm was recorded using a Cary
eclipse ﬂuorimeter with excitation and emission slit width of 5 nm.
Figure 7. Fourier deconvoluted and ﬁtted IR spectra in the amide I
region with component peaks of (a) the native state of the D67H
lysozyme variant and (b) ﬁbrils of the D67H variant measured both at
pH 5.5 and 25 °C. The ATR-FTIR spectra are reported as thick lines,
whereas the dashed lines correspond to the individual components
obtained by curve ﬁtting. Within the ﬁtted spectra, the black lines are
assigned to signals corresponding to the main chain and the gray lines
are assigned to signals corresponding to the side chains.
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of the protein after the ﬁbrils were dissolved in DMSO corres-
ponds to that of the full-length lysozyme protein (data not shown).
■ DISCUSSION
Sevenmutational variants of human lysozyme are associated with
familial non-neuropathic systemic amyloid disease in which large
quantities of the variant proteins can be deposited in vital organs,
notably the liver, spleen, and kidney.2 Detailed comparison of the
properties of the amyloidogenic variants, in particular I56T and
D67H, with those of wild-type lysozyme and a naturally
occurring and non-amyloidogenic variant (T70N) has shown
that both amyloidogenic variants have essentially identical
reductions in native state stability and in global cooperativity
relative to the wild-type protein. These changes are therefore
likely to be determinant features underlying the intrinsic
propensity of these variants to misfold and form amyloid
ﬁbrils.11,12,27 Studies of the amyloidogenic variants have shown
that partially folded species in which the β-domain and the
adjacent C-helix of the protein are unfolded, but the remainder of
the α-domain remains in its native state, can form transiently
under physiologically relevant conditions.12,15,20,27,28 It is thus
very likely that intermolecular interactions between the unfolded
regions of the protein in such intermediate species are
responsible for the initial association process that eventually
leads to ﬁbril formation (Figure 8). In accord with this mecha-
nism, we have previously shown that the stabilization of the
native state of the variant proteins consequent upon binding to
two camelid antibody fragments, referred to as cAb-HuL6 and cAb-
HuL22, is an extremely eﬀective way to restore global coopera-
tivity and thus to inhibit ﬁbril formation.27,28,31 Such a strategy
has proved to be very successful for another system, namely, the
suppression of amyloidosis and pathology associated with the
tetrameric protein transthyretin (TTR).61−64 TTR amylodosis
has been successfully inhibited by the design of small organic
compounds, which bind to the interface between monomeric
subunits within the tetramer, thereby stabilizing kinetically the
TTR tetramer architecture and inhibiting misfolding and ﬁbril
formation. Indeed, such a strategy has resulted in the successful
development of a drug for the treatment of TTR amyloid
disease.61−64
In the present study, we have investigated the eﬀects of a third
nanobody targeted to human lysozyme, denoted cAb-HuL5,
along with a stabilized analogue denoted cAb-HuL5G, on the
stability and global cooperativity of the I56T and D67H variants
and on the propensity of one of these variants, D67H, to form ﬁbrils.
H/D exchange experimentsmonitored bymass spectrometry reveal
that, under physiologically relevant conditions, cAb-HuL5 does not
suppress the transient and cooperative unfolding of the β-domain
and C-helix of the I56T and D67H variants (Figure 4).
Moreover, MS data in fact show that the rate of this local
unfolding process in both the I56T and D67H variants is
increased by a factor of 1.5−3.0 upon binding to cAb-HuL5. The
structure of the complex between cAb-HuL5 and WT-HuL
shows that the epitope of this nanobody is primarily located in
the loop between helices A and B of native lysozyme. Thus, the
epitope of cAb-HuL5 does not encompass any of the residues
that are transiently and cooperatively denatured in the amylo-
idogenic intermediates of the I56T and D67H variants.11
As the integrity of the interface between the α- and β-domains
is a key element in the maintenance of the global cooperativity,
these results suggest that cAb-HuL5 disrupts interface inter-
actions via long-range conformational eﬀects and thus facilitates
the formation of the intermediate species. In support of this
hypothesis, we found that the amide resonances of two residues
(I59 and W109) of the cAb-HuL5/WT-HuL complex and one
residue (I59) of the cAb-HuL5/I56T complex, whose side
chains point toward the interface between the α- and β-domains,
exhibit signiﬁcant chemical shift perturbations upon nanobody
binding (Figure 3c and Figure S2, Supporting Information).
The structural basis for these eﬀects is, however, likely to be
extremely subtle, as no signiﬁcant conformational deviations
Table 3. Secondary-Structure Content of Monomeric and
Fibrillar D67H HuL as Determined by Curve Fitting of the
ATR-FTIR Spectra Shown in Figure 7
monomeric D67H % ﬁbrils of D67H lysozyme %
1623 cm−1 β-sheet 24 1614 cm−1 β-sheet 20
1637 cm−1 disordered 15 1628 cm−1 β-sheet 41
1653 cm−1 α-helix +
disordered
37 1645 cm−1 α-helix +
disordered
19
1667 cm−1 turn 6 1663 cm−1 turn 17
1679 cm−1 turn 17 1677 cm−1 turn 3
1695 cm−1 β-sheet 1
Figure 8. Possible mechanism for lysozyme ﬁbril formation and its
inhibition by nanobodies. Partially unfolded intermediate species of the
protein (I) in which the C helix and the β-domain are cooperatively
unfolded self-associate through the unfolded regions to initiate oligomer
formation. This provides a template for the further aggregation of the
protein and for the development of the stable, mainly β-sheet, core
structure of the protoﬁlaments within an amyloid ﬁbril. The binding of
cAb-HuL5 to the loop connecting the A and B helices is likely to inhibit
the formation of the ﬁrst intermolecular interaction (1) or the unfolding
and reorganization of the regions of the α-domain that are native-like in
the amyloidogenic intermediate (2) but are disorganized in the ﬁbrils.
The stage at which aggregation is inhibited by the two nanobodies
studied previously, cAb-HuL6 and cAb-HuL22,28,31 is also shown for
comparison. Note that the native disulﬁde bridges, though not
represented in this scheme, are present in all species including the
ﬁbrils.
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from the WT-HuL structure are detectable for any of these
residues in the crystal structure of WT-HuL in complex with
cAbHuL5 (Figure S1, Supporting Information). The observed
increased rate of partially folded intermediate formation also
suggests that the transition state, or the ensemble of partially
unfolded HuL species, provides extra, albeit transient, inter-
actions with the nanobody, leading to a reduced kinetic barrier
for the formation of the intermediate species.
These results contrast sharply with those obtained previously
with cAb-HuL6 and cAb-HuL22, which inhibit the cooperative
unfolding of the β-domain and C-helix of amyloidogenic variants
of HuL.27,28,31 This inhibition might readily be explained by the
direct binding of the nanobodies to residues of the β-domain and
C-helix.27,28,31 However, in the case of cAb-HuL6, only 11 of the
nearly 60 residues involved in the transient unfolding of the I56T
and D67H variants are in direct contact with the nanobody,
suggesting that this nanobody does not suppress unfolding
simply bymasking the region that is destabilized by the mutation,
but in fact restores the cooperativity of the lysozyme structure
that is disrupted by the mutation through long-range structural
perturbations. This model is again supported by the fact that the
amide resonances of the residues in the interface between the α-
and β-domains, which are located far from the nanobody epitope,
including those at the positions of the amyloidogenic mutations,
have signiﬁcant chemical shift perturbations upon binding to the
nanobody cAb-HuL6.27,28 Taking together the results for cAb-
HuL5, cAb-HuL6, and cAb-HuL22, we conclude that the eﬀects
of nanobody binding on the properties of the interface between
the α- and β-domains, and thus on the global cooperativity of the
amyloidogenic lysozyme variants, are highly dependent on the
location of the epitope.
By contrast, we do not observe a clear correlation between the
location of the epitopes of the nanobodies and their apparent
ability to interfere with the formation of ﬁbrillar material by
lysozyme; indeed we observe that all three lysozyme-speciﬁc
nanobodies that we have studied, cAb-HuL5, cAb-HuL2231 and
cAb-HuL6,27,28 are capable of inhibiting aggregation while
binding to diﬀerent epitopes. Their eﬃciency to suppress ﬁbril
formation, on the other hand, does correlate strongly with the
measured aﬃnity of the nanobody:lysozyme interaction. Under
the conditions used to initiate lysozyme ﬁbril formation
(involving chemical denaturants, elevated temperature and low
pH), the binding of cAb-HuL5 to D67H is signiﬁcantly weaker
than it is under more physiological conditions; thus an excess of
nanobody is necessary to suppress ﬁbril formation fully (Figure 6).
Similarly, the KD values for the cAb-HuL22:WT-HuL and
cAb-HuL6:WT-HuL interactions are, respectively, increased
from, respectively, 35 nM and 0.7 nM under physiologically
relevant conditions to ∼1 μM31 and ∼10 nM (M.D. personal
communication) under the conditions used to trigger lysozyme
ﬁbril formation; moreover, the KD value for the cAb-HuL22:D67H
interaction is even further increased, by a factor of ﬁve, relative to
that of cAb-HuL22:WT-HuL.31 Consequently, under the
conditions used in these studies, the aﬃnity of cAb-HuL6 is
still suﬃciently high to observe full inhibition of amyloid ﬁbril by
the amyloidogenic variants of HuL at equimolar concentra-
tions27,28 whereas an excess of cAb-HuL22 is needed to achieve
this eﬀect. We note, however, that an excess of either cAb-HuL5
or cAb-HuL22 would not be necessary to inhibit lysozyme ﬁbril
formation under physiological conditions, where the dissociation
constants for their interactions with the lysozyme variants are
signiﬁcantly lower (Table 2 and refs 27, 28).
As the binding of cAb-HuL5G does not suppress the local
unfolding of the D67H variant and strongly inhibits its ﬁbril
formation, the nanobody must inﬂuence a subsequent step in the
ﬁbril formation pathway of HuL amyloidogenic variants. This
step could range from the initial dimer formation to the
formation of small oligomeric structures, preceding their
conversion into protoﬁlaments and amyloid ﬁbrils (Figure 8).
We have previously shown that the extracellular chaperone
clusterin strongly inhibits the ﬁbril formation by the I56T
lysozyme variant when present at sub-stoichiometric amounts,65
and demonstrated that the mechanism of inhibition by clusterin
is via interactions with oligomeric species that are generated
during the lag phase of the ﬁbril formation reaction.65 Although it
is possible that cAb-HuL5 binds to similar species and prevents
them from further conversion into amyloid protoﬁbrils and
ﬁbrils, the mechanism for inhibition is clearly diﬀerent as, unlike
clusterin, cAb-HuL5 binds to the monomeric form of lysozyme
and a saturating amount of nanobody to lysozyme is needed
to suppress ﬁbril formation. This result suggests that the
mechanism of inhibition most probably involves prevention of
the unfolding of the α-domain upon conversion to one of the
soluble species during this process.
In support of this hypothesis, we have found using IR
spectroscopy that the α-helical content of D67H is signiﬁcantly
reduced in the D67H ﬁbrils relative to that of the native state
(Figure 7). Furthermore, proteolytic studies of human lysozyme
ﬁbrils formed at low pH and moderate temperature have shown
that the fragments corresponding to residues 32−108, essentially
consisting of residues in the β-domain, the C-helix and much of
the α-domain, are likely to be involved in the formation of
the core of the amyloid cross-β structure, whereas the residues
forming the A, B, and D helices in the native state of lysozyme are
essentially disordered.29 These ﬁndings are also consistent with
the fact that cAb-HuL5 does not detectably bind to D67H ﬁbrils
(Figure S4, Supporting Information). This observation contrasts
strongly with those with nanobodies that we have recently
reported to interact with the intrinsically unfolded protein
α-synuclein. In these cases, the nanobodies bind to a linear
epitope in the C-terminal region of α-synuclein (the key
mediator of Parkinson’s disease), and consequently also binds to
α-synuclein in its ﬁbrillar form.66,67
We can therefore conclude from all these ﬁndings that
nanobodies are excellent reagents to probe conformational
changes as well as epitope accessibility in species populated
during amyloid ﬁbril formation pathways.32,66,67 In this report,
we have shown that cAb-HuL5 can eﬀectively probe the
existence of native-like structure of the α-domain in HuL,
thereby rendering it an extremely useful reagent in conjunction
with biophysical methods, such as AFM, ﬂuorescence micros-
copy and single molecule techniques,55 for probing the
conformation and accessibility of the α-domain in the variety
of forms of species of HuL that are populated during the process
of ﬁbril formation.
■ CONCLUSIONS
Understanding the general principles of protein folding68−74 and
misfolding24,75,76 is crucial to our understanding of the factors
that enable biological systems to self-assemble and function
normally, and to our knowledge of the origins of a wide range of
increasingly prevalent protein deposition diseases.77 Studies of
the lysozyme family of proteins by a wide range of experimental
and theoretical studies1,78,79 have provided key information
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about both of these phenomena and the nature of the link
between them.
Our earlier studies have shown that the nanobodies, cAb-
HuL6 and cAb-HuL22, can strongly inhibit ﬁbril formation
by the amyloidogenic variants of human lysozyme through
the suppression of the population of an early aggregation-prone
intermediate. In the present study, we have shown that lysozyme
ﬁbril formation can be inhibited by intervention at a stage of the
aggregation process that is subsequent to the formation of an
aggregation-prone intermediate. This ﬁnding, therefore, provides
further evidence of the potential of speciﬁc antibody-based
therapies directed against diﬀerent types of protein misfolding
diseases.28,32
The present ﬁndings also highlight the beneﬁts of nanobodies
as probes to provide a deeper knowledge of the underlying
mechanism of human lysozyme amyloid formation as well as a
better understanding of the structural features of species
populated on the ﬁbril formation pathway of human lysozyme.
We have also shown by replacing the sequence of the antigen
binding loops of the extremely stable and aggregation-resistant
nanobody cAb-HuL6 with the sequences of those of cAb-HuL5,
that nanobodies are very amenable to modiﬁcations by the
method of protein engineering to enhance their properties.
Further improvement, via in vitro evolution techniques, to
enhance the aﬃnity of cAb-HuL5G for lysozyme, can be
envisaged to improve the power of the nanobody to inhibit
HuL ﬁbril formation. The results that have been obtained in the
work for lysozyme should in addition be beneﬁcial for
fundamental experimental investigations on protein misfolding
and aggregation and they indicate the potential for the
development of rational therapeutic strategies to combat the
family of diseases involving the misfolding of a wide variety of
proteins into amyloid ﬁbrils.
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